

MAR 17 2005

Subst. Form PTO-1449 APPLICANT'S INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 18525/04011	Serial No.: 09/632,036
	Applicant: Kaumaya, et al.	
	Filing Date: August 3, 2000	Group: 1642

U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Date
SR	AA	5,876,712	March 2, 1999	Cheever, et al.			Jun. 6, 1995
	AB						

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Subcl.	Translation?
SR	AC	94/07531	April 14, 1994	WO			
	AD	97/38011	October 16, 1997	WO			

OTHER PRIOR ART

SR	AE	Supplementary European Search Report dated August 10, 2004.					
SR	AF	"Peptide Vaccines Incorporating a "Promiscuous" T-cell Epitope bypass Certain Haplotype Restricted Immune Responses and Provide Broad Spectrum Immunogenicity" by Kaumaya, et al., <u>Journal of Molecular Recognition</u> , Vol. 6, 81-94 (1993).					
	AG	"Human T-Lymphotropic Virus Type 1 Peptides in Chimeric and Multivalent Constructs with Promiscuous T-Cell Epitopes Enhance Immunogenicity and Overcome Genetic Restriction" by Lairmore, et al., <u>Journal of Virology</u> , Oct. 1995, vol. 69, No. 10, p. 6077-6089.					
	AH	"Subunit Peptide Cancer Vaccines Targeting Activating Mutations of the p21 RAS Proto-Oncogene" by Triozi, et al., <u>Biomedical Peptides, Proteins and Nucleic Acids</u> , Vol. 1, 185-192 (1995).					
	AI	"Granulocyte-Macrophage Colony Stimulating Factor: An effective Adjuvant for Protein and Peptide-Based Vaccines" by Disis, et al., <u>Blood</u> , Vol. 88, No. 1, July 1, 1996, p. 202-210.					
	AJ	"Identification of HER2/neu-Derived Peptide Epitopes Recognized by Gastric Cancer-Specific Cytotoxic T Lymphocytes" by Kono, et al., <u>Int. J. Cancer</u> , 78, 202-208 (1998).					
	AK	"Identification of HLA-A3-restricted Cytotoxic T Lymphocyte Epitopes from Carcinoembryonic Antigen and HER-2/neu by Primary <i>in Vitro</i> Immunization with Peptide-pulsed Dendritic Cells" by Kawashima, et al., <u>Cancer Research</u> , 59, 431-435, January 15, 1999.					
	AL	"Immunization to Oncogenic HER-2/neu Protein with Peptide Based Vaccines" by Disis, et al., <u>Proceedings of the Annual Meeting of the American Association for Cancer Research</u> , New York, New York, Vol. 36, March 1995, p. 251.					
	AM	"T-Cell, Adhesion, and B-Cell Epitopes of the Cell Surface <i>Streptococcus mutans</i> Protein Antigen I/II" by Kelly, et al., <u>Infection and Immunity</u> , Vol. 63, No. 9, Sept. 1995, p 3649-3658.					
	AN	"Antigenicity and immunogenicity of multiple antigen peptides (MAP) containing <i>P. vivax</i> CS epitopes in <i>Aotus</i> monkeys" by Herrera, et al., <u>Parasite Immunology</u> , 1997: 19: 161-170.					
	AO	"A novel human HER2-derived peptide homologous to the mouse K ^d -restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals" by Okugawa, et al., <u>Eur. J. Immunol</u> , 2000, 30:3338-3346.					
	AP	"A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses" by Dakappagari, et al., <u>The Journal of Immunology</u> , April 15, 2003, Vol. 170, No. 8, p. 4242-4253.					
	AQ	"Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide" by Frangione-Beebe, et al., <u>Vaccine</u> , 19 (2001) 1068-1081.					

Examiner:

Date Considered:

6/2/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.